CellCarta and Lunit entered a partnership to integrate Lunit’s AI pathology tools (Scope) with CellCarta’s clinical trial pathology services. The companies said the combined offering will support biomarker development, image analysis, and clinical trial testing. CellCarta framed the deal as responding to sponsor demand for faster evidence generation, while Lunit emphasized that scalable adoption requires interoperability and operational readiness with real-world trial workflows. The partnership also calls for pilot evaluations across trial operations and AI image analysis. The agreement was reported without disclosed financial terms, and the firms said they plan to expand the collaboration as additional use cases validate.